Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Healthcare and biotech stocks have had a rough run since the giddy heights of the Covid pandemic. But now could be the perfect time to consider investing in these beaten-down but high-growth sectors.

If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Biotech firms use AI in trials to target patients more ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied about 35% over the past six months (as of Nov. 20, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 12%). Year to ...

Bay Area startup ASC Therapeutics filed for bankruptcy on Wednesday, marking the end of the line for the gene and cell therapy researcher even as Health and Human Services Secretary Robert F. Kennedy ...

In this piece, we discuss the 10 Best Small-Cap Biotech Stocks to Buy According to Analysts. Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention. This ...

Something unusual is happening to biotech stocks: They’re going up. A drug-pricing deal between Pfizer and the White House and a spate of deals have sent the SPDR S&P Biotech exchange-traded fund up 9 ...

Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink. In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle Masson came ...